SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

16 Nov 2018 Evaluate

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific meeting of the Infectious Diseases Society of America (IDSA).

The company's four abstracts were accepted for poster presentations at the IDWeek 2018. These posters covered the efficacy results from the plea clinical trial, as well as supportive in vitro efficacy data from an AMR Surveillance study.

Venus Remedies is a pharmaceutical manufacturing company. The company is engaged in manufacturing products catering to various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties.

Venus Remedies Share Price

1042.35 3.25 (0.31%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×